Annual report
4078.TEDINET S100R306
Period2022-04-01 → 2023-03-31
Filed2023-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥83.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥80.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥84.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥87.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥89.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.4bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥7.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥4.9bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥8.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.0bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.6bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.0bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥9.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥6.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.5bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.6bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥7.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥128.0bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥123.9bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥123.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥121.6bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥120.1bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥43.3bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥41.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥84.7bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥82.7bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥79.3bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥81.5bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥80.3bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥12.4bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥12.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.2bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.1bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥11.2bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥773m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.4bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥68m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥64m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥144.85 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥407.06 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-166.58 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥150.84 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥210.34 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,970.11 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,875.69 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,502.33 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,657.04 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,598.89 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 62.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.6% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.3% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | -3.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,013 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 2,024 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 2,009 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 2,003 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 1,964 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥42.8bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥41.1bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥34.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥37.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥40.6bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥285m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥2.6bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.1bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.8bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥943m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.0bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.6bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥5.2bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.4bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥4.6bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | −¥4.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.0bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥87.8bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥87.6bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥88.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥88.7bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥84.6bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥35.0bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥35.0bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥52.8bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥52.6bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥51.6bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥55.5bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥55.3bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.9bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥6.9bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥85.72 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥278.97 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-245.57 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.38 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥114.76 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥75 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,259.43 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,253.05 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,064.29 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,297.38 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,293.74 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 60.1% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.1% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.5% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -7.7% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 17,000,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 769 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 773 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 774 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 776 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 768 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 57
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥64m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥146m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥1.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥1.0bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥13.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥2.2bn |
| Chemicalreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥3.3bn |
| Chemicalreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥4.0bn |
| Chemicalreportable segment | employees | at 2023-03-31 | 1685 pure |
| Chemicalreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥76.7bn |
| Chemicalreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥76.0bn |
| Chemicalreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥757m |
| Chemicalreportable segment | segment assets | at 2023-03-31 | ¥100.8bn |
| Chemicalreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥6.4bn |
| Medicine And Healthcarereportable segment | capex | 2022-04-01 → 2023-03-31 | ¥207m |
| Medicine And Healthcarereportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥237m |
| Medicine And Healthcarereportable segment | employees | at 2023-03-31 | 271 pure |
| Medicine And Healthcarereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥8.1bn |
| Medicine And Healthcarereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥7.9bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥270m |
| Medicine And Healthcarereportable segment | segment assets | at 2023-03-31 | ¥13.6bn |
| Medicine And Healthcarereportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥272m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥3.5bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥4.3bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥84.9bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥83.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥1.0bn |
| —segment total | segment assets | at 2023-03-31 | ¥114.4bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥6.6bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥197m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥153m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥13.9bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥2.1bn |
| Chemicalreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Chemicalreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥4.0bn |
| Chemicalreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥73.7bn |
| Chemicalreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥72.2bn |
| Chemicalreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| Chemicalreportable segment | segment assets | at 2022-03-31 | ¥96.5bn |
| Chemicalreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥9.2bn |
| Medicine And Healthcarereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥794m |
| Medicine And Healthcarereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥228m |
| Medicine And Healthcarereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥8.2bn |
| Medicine And Healthcarereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥7.9bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥292m |
| Medicine And Healthcarereportable segment | segment assets | at 2022-03-31 | ¥13.5bn |
| Medicine And Healthcarereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥418m |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥3.4bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥4.2bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥81.8bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥80.1bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥1.7bn |
| —segment total | segment assets | at 2022-03-31 | ¥110.0bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Chemicalreportable segment | employees | at 2023-03-31 | 712 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,685
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase decrease in notes and accounts payable trade ope cf | CurrentYearDuration | -1065000000 | JPY |
| Other net ope cf | Prior1YearDuration | -576000000 | JPY |
| Other net ope cf | CurrentYearDuration | -1500000000 | JPY |
| Subtotal ope cf | Prior1YearDuration | 7852000000 | JPY |
| Subtotal ope cf | CurrentYearDuration | 2274000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YearDuration | 227000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYearDuration | 151000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YearDuration | -71000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYearDuration | -79000000 | JPY |
| Proceeds from subsidy ope cf | Prior1YearDuration | － | JPY |
| Proceeds from subsidy ope cf | CurrentYearDuration | 771000000 | JPY |
| Proceeds from insurance income ope cf | Prior1YearDuration | － | JPY |
| Proceeds from insurance income ope cf | CurrentYearDuration | 521000000 | JPY |
| Income taxes paid ope cf | Prior1YearDuration | -1440000000 | JPY |
| Income taxes paid ope cf | CurrentYearDuration | -2866000000 | JPY |
| Net cash provided by used in operating activities | Prior1YearDuration | 6567000000 | JPY |
| Net cash provided by used in operating activities | CurrentYearDuration | 773000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YearDuration | -5064000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYearDuration | -2658000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1YearDuration | 60000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYearDuration | 180000000 | JPY |
| Purchase of investment securities inv cf | Prior1YearDuration | -30000000 | JPY |
| Purchase of investment securities inv cf | CurrentYearDuration | -94000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YearDuration | 3591000000 | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYearDuration | 193000000 | JPY |
| Other net inv cf | Prior1YearDuration | -211000000 | JPY |
| Other net inv cf | CurrentYearDuration | -241000000 | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration | -1654000000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -2620000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YearDuration | -1394000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYearDuration | 5669000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YearDuration | 300000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYearDuration | 2300000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -2410000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -3316000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | -1500000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -0 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -589000000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -1289000000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1YearDuration | -58000000 | JPY |
| Dividends paid to non controlling interests fin cf | CurrentYearDuration | -77000000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | Prior1YearDuration | -0 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | CurrentYearDuration | -0 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -5654000000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | 3283000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 138000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 202000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | -603000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 1638000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 11153000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |